Zacks Investment Research upgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a sell rating to a hold rating in a report released on Tuesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities research analysts also recently weighed in on the company. CIBC began coverage on Seres Therapeutics in a report on Friday, October 13th. They issued an outperform rating and a $19.00 price target for the company. Oppenheimer Holdings, Inc. started coverage on Seres Therapeutics in a report on Thursday, October 12th. They issued an outperform rating and a $19.00 price target for the company. Citigroup Inc. started coverage on Seres Therapeutics in a report on Thursday, October 12th. They set a positive rating and a $19.00 target price for the company. Seaport Global Securities reaffirmed a buy rating and set a $20.00 target price on shares of Seres Therapeutics in a report on Friday, October 6th. Finally, Cowen and Company reaffirmed a buy rating on shares of Seres Therapeutics in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $18.00.

Shares of Seres Therapeutics (NASDAQ MCRB) traded up $0.09 during mid-day trading on Tuesday, reaching $9.41. The company had a trading volume of 185,507 shares, compared to its average volume of 211,000. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $17.42. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company’s quarterly revenue was up 76.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.46) earnings per share. equities analysts anticipate that Seres Therapeutics will post -2.34 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/17/seres-therapeutics-inc-mcrb-upgraded-at-zacks-investment-research.html.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC acquired a new position in Seres Therapeutics during the second quarter worth $114,000. Cubist Systematic Strategies LLC acquired a new position in Seres Therapeutics during the third quarter worth $170,000. American International Group Inc. boosted its stake in Seres Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Aperio Group LLC acquired a new position in Seres Therapeutics during the third quarter worth $191,000. Finally, Ironwood Investment Management LLC acquired a new position in Seres Therapeutics during the third quarter worth $221,000. Hedge funds and other institutional investors own 74.77% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.